Medically reviewed by Dr. Jyoti Rao, Consultant, Medical Affairs | Published June 2026 | Last reviewed June 2026
Key Takeaways
- Multidisciplinary care matters because tafamidis treatment requires long-term management rather than a single prescribing decision.
- Access, refill continuity, monitoring, and symptom reassessment often determine whether treatment can be maintained over time.
- Coordinated follow-up reduces fragmentation through shared documentation and clear handoffs, supporting continuity.
- Coordination improves continuity and interpretation, but it doesn’t eliminate access barriers or guarantee persistence.
Why Tafamidis Care Is Longitudinal, Not a Single Prescription
In ATTR-CM, tafamidis is best understood as part of an ongoing care pathway rather than a single prescribing decision. Its practical value depends on whether treatment can be started, accessed, continued, and revisited across routine follow-up, which makes treatment persistence and adherence integral components of clinical management, not secondary administrative concerns. That’s the same continuity that makes tafamidis a chronic therapy rather than a single treatment decision.
What the Care Team Coordinates over Time
That is where multidisciplinary care becomes clinically relevant. According to consensus guidance and specialized-center experience, ATTR-CM management requires repeated, structured coordination spanning diagnosis review, medication initiation, authorization, refill continuity, tolerance checks, and longitudinal surveillance, with a team that often extends beyond cardiology to nursing, pharmacy, imaging, laboratory, and patient support services. The challenge is not only choosing tafamidis, but maintaining continuity of treatment and follow-up over time.
How Coordinated Follow-Up Improves Continuity
Coordinated follow-up improves treatment continuity. Shared documentation and clear handoffs between specialty and community clinicians reduce the risk of missed refills, lapsed authorizations, and gaps in clinical surveillance that interrupt exposure when patients move between diagnosis, initiation, and chronic care. Although these are operational processes, they’re the primary determinants of real-world treatment adherence and persistence.
What Coordination Does and Does Not Solve
Even so, real-world persistence can still be disrupted by access barriers, visit burden, and care transitions, so the primary value of multidisciplinary care lies in making ongoing tafamidis treatment more feasible and clinically meaningful rather than eliminating all sources of treatment uncertainty.
Clinical Decision Point
When tafamidis continuity is at risk due to repeated authorization delays, refill gaps, fragmented follow-up, or inadequate surveillance, the appropriate response is to strengthen care coordination rather than to reconsider the therapeutic decision. Assign clear responsibility for refill management, clinical monitoring, and care transitions between specialty and community settings, and consider amyloidosis-center involvement. Effective multidisciplinary coordination supports treatment continuity and appropriate clinical follow-up. It does not, on its own, remove access barriers.
Frequently Asked Questions
What’s the role of multidisciplinary care in supporting tafamidis therapy in ATTR-CM?
Successful tafamidis treatment depends on diagnosis confirmation, access, persistence, and repeated reassessment, so coordinated follow-up often matters as much as the initial prescription.
Which aspects of tafamidis management are most susceptible to disruption in clinical practice?
Authorization, refill continuity, symptom surveillance, tolerance review, and handoffs between specialty and community settings are the main pressure points.
What does multidisciplinary care improve most reliably?
It improves continuity, documentation, and practical follow-through. It makes treatment more effectively coordinated, but it doesn’t eliminate access barriers or guarantee persistence.
When should coordination be escalated?
When refill gaps, authorization delays, or fragmented surveillance threaten continuity, responsibilities for each aspect of care should be clarified and amyloidosis-center involvement considered.
Part of the Spotlight On ATTR-CM resource center.
References:
- World Heart Federation Consensus on Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM). PubMed
- Best Practices in Specialized Amyloidosis Centers in the United States. PubMed
- Baseline characteristics and secondary medication adherence among Medicare patients diagnosed with ATTR-CM and/or receiving tafamidis prescriptions. PubMed
- Improving Long-Term Outcomes in ATTR-CM: Aiming at a Moving Target. JACC CardioOncology
This content is intended for healthcare professionals for educational purposes and is not a substitute for individual clinical judgment. It was developed with AI assistance and reviewed by a qualified healthcare professional for clinical accuracy prior to publication.